Position in EXEL
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$4,604,933
-$9,038,931 QoQ
Shares Held
84,634
-73.4% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#181
of 754 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Merit Financial Group, LLC holds $38,062,980 across 57 Biotechnology names. EXEL ranks #3 (12.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
12,218 | $6,069,041 | |
| 2 | INCY |
Incyte Corp
|
50,561 | $5,731,591 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
84,634 | $4,604,933 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,333 | $2,078,255 | |
| 5 | MRNA |
Moderna, Inc.
|
25,205 | $1,765,104 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
5,380 | $1,296,414 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
20,198 | $1,155,727 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
11,908 | $1,035,397 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,604,933 | 84,634 | Shares | Other | 2026-07-20 | |
| 2026-03-31 | $13,643,864 | 318,113 | Shares | Other | 2026-04-15 | |
| 2025-12-31 | $3,811,279 | 86,956 | Shares | Other | 2026-01-26 | |
| 2025-09-30 | $2,863,782 | 69,341 | Shares | Other | 2025-11-07 | |
| 2025-06-30 | $1,796,700 | 40,760 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $1,235,084 | 33,453 | Shares | Sole | 2025-04-09 | |
| 2024-12-31 | $437,162 | 13,128 | Shares | Sole | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||